AP2646A - Peptide sequences and compositions - Google Patents

Peptide sequences and compositions

Info

Publication number
AP2646A
AP2646A AP2008004571A AP2008004571A AP2646A AP 2646 A AP2646 A AP 2646A AP 2008004571 A AP2008004571 A AP 2008004571A AP 2008004571 A AP2008004571 A AP 2008004571A AP 2646 A AP2646 A AP 2646A
Authority
AP
ARIPO
Prior art keywords
compositions
peptide sequences
peptide
sequences
Prior art date
Application number
AP2008004571A
Other languages
English (en)
Other versions
AP2008004571A0 (en
Inventor
Gregory Alan Stoloff
Wilson Romero Caparros-Wanderley
Original Assignee
Pep Tcell Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38109631&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP2646(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GB0602416A external-priority patent/GB0602416D0/en
Application filed by Pep Tcell Ltd filed Critical Pep Tcell Ltd
Publication of AP2008004571A0 publication Critical patent/AP2008004571A0/xx
Application granted granted Critical
Publication of AP2646A publication Critical patent/AP2646A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/11—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/572—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 cytotoxic response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16211—Influenzavirus B, i.e. influenza B virus
    • C12N2760/16271—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Communicable Diseases (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Transplantation (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AP2008004571A 2006-02-07 2007-02-05 Peptide sequences and compositions AP2646A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0602416A GB0602416D0 (en) 2006-02-07 2006-02-07 Peptide sequences and compositions
GBGB0613977.8A GB0613977D0 (en) 2006-02-07 2006-07-13 Peptide sequences and compositions
PCT/GB2007/000383 WO2007091030A2 (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Publications (2)

Publication Number Publication Date
AP2008004571A0 AP2008004571A0 (en) 2008-08-31
AP2646A true AP2646A (en) 2013-04-17

Family

ID=38109631

Family Applications (1)

Application Number Title Priority Date Filing Date
AP2008004571A AP2646A (en) 2006-02-07 2007-02-05 Peptide sequences and compositions

Country Status (23)

Country Link
US (10) US8475802B2 (pl)
EP (6) EP3263589B1 (pl)
JP (1) JP5603551B2 (pl)
KR (1) KR20080100441A (pl)
CN (3) CN102382179B (pl)
AP (1) AP2646A (pl)
AT (1) ATE534660T1 (pl)
AU (1) AU2007213562A1 (pl)
BR (1) BRPI0707543B8 (pl)
CA (1) CA2641602A1 (pl)
DK (4) DK2383285T3 (pl)
EA (1) EA017387B1 (pl)
ES (4) ES2790730T3 (pl)
GB (1) GB0613977D0 (pl)
HK (1) HK1249115A1 (pl)
IL (2) IL193232A (pl)
MX (1) MX2008010113A (pl)
NO (1) NO20083416L (pl)
NZ (1) NZ570553A (pl)
PL (4) PL3263589T3 (pl)
PT (1) PT1991563E (pl)
SG (1) SG169392A1 (pl)
WO (1) WO2007091030A2 (pl)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0716992D0 (en) 2007-08-31 2007-10-10 Immune Targeting Systems Its L Influenza antigen delivery vectors and constructs
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions
US8097419B2 (en) 2006-09-12 2012-01-17 Longhorn Vaccines & Diagnostics Llc Compositions and method for rapid, real-time detection of influenza A virus (H1N1) swine 2009
US8080645B2 (en) 2007-10-01 2011-12-20 Longhorn Vaccines & Diagnostics Llc Biological specimen collection/transport compositions and methods
US9481912B2 (en) 2006-09-12 2016-11-01 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and identifying nucleic acid sequences in biological samples
HUE025149T2 (hu) 2007-08-02 2016-01-28 Biondvax Pharmaceuticals Ltd Multimer multiepitóp influenza vakcinák
US11041215B2 (en) 2007-08-24 2021-06-22 Longhorn Vaccines And Diagnostics, Llc PCR ready compositions and methods for detecting and identifying nucleic acid sequences
US9683256B2 (en) 2007-10-01 2017-06-20 Longhorn Vaccines And Diagnostics, Llc Biological specimen collection and transport system
US10004799B2 (en) 2007-08-27 2018-06-26 Longhorn Vaccines And Diagnostics, Llc Composite antigenic sequences and vaccines
AU2008293504B2 (en) 2007-08-27 2012-04-12 Longhorn Vaccines & Diagnostics, Llc Immunogenic compositions and methods
AU2008343745B2 (en) 2007-10-01 2012-05-10 Longhorn Vaccines & Diagnostics Llc Biological specimen collection and transport system and methods of use
US11041216B2 (en) 2007-10-01 2021-06-22 Longhorn Vaccines And Diagnostics, Llc Compositions and methods for detecting and quantifying nucleic acid sequences in blood samples
GB0719526D0 (en) 2007-10-05 2007-11-14 Isis Innovation Compositions and methods
EP2072529A1 (en) * 2007-12-21 2009-06-24 basisnote AG MHC rapid assay used for the customization of odours
FR2962739B1 (fr) * 2010-07-13 2014-01-31 Univ Claude Bernard Lyon Souches virales modifiees et procede pour ameliorer la production de semences vaccinales de virus influenza
US9303070B2 (en) 2011-02-22 2016-04-05 Biondvax Pharmaceuticals Ltd. Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines
WO2013093514A2 (en) * 2011-12-23 2013-06-27 Retroscreen Virology Ltd Vaccines - peptides
EP3494989A1 (en) 2012-01-26 2019-06-12 Longhorn Vaccines and Diagnostics, LLC Composite antigenic sequences and vaccines
CA2970211A1 (en) * 2014-12-10 2016-06-16 Vaxsia Biomedical Inc. Novel protein structure produced by effective antibody used for immunization
US9976136B2 (en) 2015-05-14 2018-05-22 Longhorn Vaccines And Diagnostics, Llc Rapid methods for the extraction of nucleic acids from biological samples
CN106310214A (zh) * 2015-06-30 2017-01-11 中国科学院上海巴斯德研究所 流感病毒蛋白与宿主蛋白cpsf30的相互作用在抑制癌细胞增殖中的应用
JP2019064924A (ja) * 2016-02-24 2019-04-25 Ａｇｃ株式会社 インフルエンザワクチン
KR101888751B1 (ko) * 2016-09-22 2018-09-21 이화여자대학교 산학협력단 인플루엔자 b 백신
JP2020515283A (ja) * 2016-12-28 2020-05-28 インブバックス，インコーポレーテッド インフルエンザワクチン
WO2019124557A1 (ja) * 2017-12-21 2019-06-27 株式会社グリーンバイオメッド 交差免疫抗原ワクチン及びその調製方法
EP4185601A1 (en) * 2020-07-21 2023-05-31 Flugen, Inc. Influenza virus backbone

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050099088A1 (en) * 2003-11-07 2005-05-12 Totankako Co., Ltd. Commutator
WO2005120564A2 (en) * 2004-06-11 2005-12-22 Curelab, Inc. Vaccine compositions and methods

Family Cites Families (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4981782A (en) 1987-05-14 1991-01-01 Sri International Synthetic peptides for diagnosis and prevention of influenza virus infection and their use
US5741493A (en) * 1991-01-24 1998-04-21 Pasteur Merieux Serums Et Vaccins Vaccine composition against influenza, with synergic effects, containing influenza virus core as an additive
IL101639A0 (en) * 1992-04-17 1992-12-30 Yeda Res & Dev Recombinant influenza vaccines
AU4998993A (en) * 1992-08-07 1994-03-03 Epimmune, Inc. Hla binding peptides and their uses
US20040087521A1 (en) * 1993-03-18 2004-05-06 Merck & Co., Inc. Nucleic acid pharmaceuticals-influenza matrix
IL109664A0 (en) 1993-05-18 1994-08-26 Rijksuniversiteit Peptides of human influenza virus for use in human t cell response inducing compositions
US6939546B2 (en) 1993-05-21 2005-09-06 The United States Of America As Represented By The Secretary Of The Army Model for testing immunogenicity of peptides
FR2718452B1 (fr) * 1994-04-06 1996-06-28 Pf Medicament Elément d'immunogène, agent immunogène, composition pharmaceutique et procédé de préparation.
AU3727895A (en) 1994-09-30 1996-04-26 St. Jude Children's Research Hospital Nucleic acid encoding mutant matrix proteins useful for attenuation or enhancement of influenza a virus
US7269219B1 (en) * 1997-02-14 2007-09-11 At&T Corp. Non-linear quantizer for video coding
IL127331A0 (en) 1998-11-30 1999-09-22 Yeda Res & Dev Peptide-based vaccine for influenza
JP2001151698A (ja) * 1999-09-10 2001-06-05 Nichiko Pharmaceutical Co Ltd インフルエンザワクチン
AU2002223398A1 (en) 2000-08-10 2002-04-08 Tsinghua University A vaccine for influenza virus and its preparation
AU2356002A (en) * 2000-09-25 2002-04-02 Polymun Scient Immunbio Forsch Live vaccine and method of manufacture
US6906169B2 (en) * 2001-05-25 2005-06-14 United Biomedical, Inc. Immunogenic peptide composition comprising measles virus Fprotein Thelper cell epitope (MUFThl-16) and N-terminus of β-amyloid peptide
CA2517181C (en) * 2003-02-25 2013-07-16 Medimmune Vaccines, Inc. Methods of producing influenza vaccine compositions
US20040223976A1 (en) * 2003-03-07 2004-11-11 Elisabetta Bianchi Influenza virus vaccine
US8592197B2 (en) * 2003-07-11 2013-11-26 Novavax, Inc. Functional influenza virus-like particles (VLPs)
FR2863758B1 (fr) * 2003-12-11 2006-07-14 Centre Nat Rech Scient Cellule de commande electronique pour diode electroluminescente organique d'afficheur a matrice active, procedes de fonctionnement et afficheur
GB0408164D0 (en) 2004-04-13 2004-05-19 Immune Targeting Systems Ltd Antigen delivery vectors and constructs
JP5331340B2 (ja) 2004-05-18 2013-10-30 バイカル インコーポレイテッド インフルエンザウィルスワクチン組成物、及びその使用方法
CN103451158B (zh) * 2005-04-21 2018-11-23 佛罗里达大学研究基金公司 用于犬科动物中呼吸系统疾病控制的物质和方法
US20070116717A1 (en) 2005-08-01 2007-05-24 Shneider Alexander M Influenza vaccine compositions and methods
WO2007092792A2 (en) 2006-02-02 2007-08-16 Globeimmune, Inc. Yeast-based vaccine for inducing an immune response
GB0613977D0 (en) * 2006-02-07 2006-08-23 Peptcell Ltd Peptide sequences and compositions

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050099088A1 (en) * 2003-11-07 2005-05-12 Totankako Co., Ltd. Commutator
WO2005120564A2 (en) * 2004-06-11 2005-12-22 Curelab, Inc. Vaccine compositions and methods

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
BOON A C M ET AL: "Functional profile of human influenza virus-specific cytotoxic T lmyphocyte activity is influenced by interleukin-2 concentration and epitope specificity", CLINICAL AND EXPERIMENTAL IMMUNOLOGY, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 142, 1 January 2005 (2005-01-01), pages 45-52, XP002442450, ISSN: 0009-9104, DOI: 10.1111/J.1365-2249.2005.02880.X *
DATABASE UniProt 1 November 1996 (1996-11-01), CASTRUCCI M ET AL.: "Genetic reassortment between avian and human influenza A virus" XP002442455 accession no. Q67194 *
HALL RM & AIR GM: "Variation in Nucleotide Sequences Coding for the N-Terminal Regions of the Matrix and Nonstructural Proteins of Influenza A Viruses" JOURNAL OF VIROLOGY, vol. 38, no. 1, April 1981 (1981-04), pages 1-7, XP002442449 *
TANG Y ET AL: "ISOLATION AND CHARACTERIZATION OF H3N2 INFLUENZA A VIRUS FROM TURKEYS", AVIAN DISEASES, AMERICAN ASSOCIATION OF AVIAN PATHOLOGISTS, KENNET SQ., PA, US, vol. 49, no. 2, June 2005 (2005-06), pages 207-213, XP008080091, ISSN: 0005-2086 -& DATABASE EBI 7 December 2004 (2004-12-07), XP002442454,accession no. Q5UAH5 *
TAUBENBERGER JK ET AL: "Initial Genetic Characterization of the 1918 "Spanish" Influenza Virus" SCIENCE, vol. 275, 21 March 1997 (1997-03-21), pages 1793-1796, XP002442448 -& DATABASE UniProt 1 July 1997 (1997-07-01), XP002442456 accession no. O10427 *

Also Published As

Publication number Publication date
US8444995B2 (en) 2013-05-21
SG169392A1 (en) 2011-03-30
AU2007213562A1 (en) 2007-08-16
CA2641602A1 (en) 2007-08-16
EP1991563A2 (en) 2008-11-19
BRPI0707543B1 (pt) 2020-11-24
CN102382179B (zh) 2014-01-22
US20170028053A1 (en) 2017-02-02
EP2383284A3 (en) 2012-05-30
EP3263589B1 (en) 2020-03-25
BRPI0707543B8 (pt) 2021-05-25
CN101395176A (zh) 2009-03-25
WO2007091030A2 (en) 2007-08-16
EP3320918A2 (en) 2018-05-16
DK1991563T3 (da) 2012-01-23
US20120219575A1 (en) 2012-08-30
WO2007091030A3 (en) 2007-11-08
US10335480B2 (en) 2019-07-02
DK2383285T3 (en) 2017-08-28
HK1249115A1 (zh) 2018-10-26
IL251867A0 (en) 2017-06-29
US10279032B2 (en) 2019-05-07
EP2383285A3 (en) 2012-05-16
IL193232A (en) 2017-05-29
US20100047275A1 (en) 2010-02-25
ATE534660T1 (de) 2011-12-15
US20130243804A1 (en) 2013-09-19
EP3263589A3 (en) 2018-02-14
NO20083416L (no) 2008-11-07
EP3320918A3 (en) 2018-08-01
AP2008004571A0 (en) 2008-08-31
EP3620463A1 (en) 2020-03-11
DK3263589T3 (da) 2020-05-11
CN102807608B (zh) 2015-01-21
JP5603551B2 (ja) 2014-10-08
IL251867B (en) 2018-06-28
EA200870237A1 (ru) 2009-06-30
US20200397889A1 (en) 2020-12-24
AU2007213562A2 (en) 2008-11-20
US20190201519A1 (en) 2019-07-04
BRPI0707543A2 (pt) 2011-05-03
EP2383285A2 (en) 2011-11-02
EA017387B1 (ru) 2012-12-28
EP3263589A2 (en) 2018-01-03
EP2383284B1 (en) 2016-08-24
DK3263589T5 (da) 2020-05-25
US8475802B2 (en) 2013-07-02
PT1991563E (pt) 2011-12-29
GB0613977D0 (en) 2006-08-23
EP2383284A2 (en) 2011-11-02
US9889191B2 (en) 2018-02-13
PL2383284T3 (pl) 2017-07-31
ES2374841T3 (es) 2012-02-22
US20180185470A1 (en) 2018-07-05
US20230233660A1 (en) 2023-07-27
DK2383284T3 (en) 2016-12-12
KR20080100441A (ko) 2008-11-18
ES2790730T3 (es) 2020-10-29
EP1991563B1 (en) 2011-11-23
CN102807608A (zh) 2012-12-05
US11439702B2 (en) 2022-09-13
US10765734B2 (en) 2020-09-08
MX2008010113A (es) 2009-01-19
CN101395176B (zh) 2013-02-06
ES2611034T3 (es) 2017-05-04
CN102382179A (zh) 2012-03-21
JP2009526028A (ja) 2009-07-16
PL1991563T3 (pl) 2012-02-29
US20180147277A1 (en) 2018-05-31
NZ570553A (en) 2012-08-31
PL3263589T3 (pl) 2020-07-13
EP2383285B1 (en) 2017-07-12
IL193232A0 (en) 2009-02-11
ES2635590T3 (es) 2017-10-04
PL2383285T3 (pl) 2017-11-30
US9446116B2 (en) 2016-09-20
US20190365883A1 (en) 2019-12-05

Similar Documents

Publication Publication Date Title
HK1249115A1 (zh) 肽序列和組合物
ZA201000914B (en) Peptide sequences and compositions
EP1976864A4 (en) NEW PEPTIDE AND ITS USE
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
EP2017283A4 (en) Peptides
EP2101731A4 (en) PROCESSES AND COMPOSITIONS WITH END OXIFES
GB0622399D0 (en) Novel compositions and uses thereof
EP2088865A4 (en) METHODS AND COMPOSITIONS AROUND GUGGULPHOSPHOLIPIDS
GB0617171D0 (en) Novel compositions and methods
IL195525A0 (en) Replikin peptides and uses thereof
GB0604187D0 (en) Peptide and uses thereof
EP1998753A4 (en) COMPOSITIONS FOR MAJOR DEPOSITION AND USES THEREOF
PL2392587T3 (pl) Sekwencje i kompozycje peptydów
GB0618748D0 (en) Peptide
GB0605774D0 (en) Peptide
EP2010141A4 (en) HIGH DEPOSITION COMPOSITIONS AND USES THEREOF
EP2091959A4 (en) IMPROVED PEPTIDE COMPOSITION
ZA200806753B (en) Peptide sequences and compositions
GB0604920D0 (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
IL192800A0 (en) Fgf2-binding peptides and uses thereof
PL378824A1 (pl) Peptyd i jego zastosowanie
GB0612873D0 (en) Isolated peptides and uses thereof
GB0625230D0 (en) Compositions and methods
GB0616269D0 (en) Methods and compositions